-+ 0.00%
-+ 0.00%
-+ 0.00%

Mangoceuticals signs business combination deal with Nuclea Energy

PUBT·07/30/2026 11:07:49
Listen to the news
Mangoceuticals signs business combination deal with Nuclea Energy
  • Mangoceuticals struck a business combination agreement with Nuclea Energy, an advanced nuclear developer focused on the lead-cooled Morpheus microreactor.
  • A newly formed Mangoceuticals subsidiary will merge with Nuclea, leaving Nuclea as an indirect wholly owned subsidiary of Mangoceuticals.
  • Nuclea shareholders will receive exchangeable shares, convertible one-for-one into Mangoceuticals common stock, with economics and votes designed to match.
  • Rights tied to the exchangeable shares will be capped at 19.99% of Mangoceuticals shares outstanding at closing until stockholder and Nasdaq approvals.
  • Morpheus is in conceptual design, targeted at 3.5 MWe to 50 MWe output, with an 18-month roadmap toward regulatory and commercial readiness.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mangoceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300700PRIMZONEFULLFEED9800729) on July 30, 2026, and is solely responsible for the information contained therein.